Table 1.
Topical application deltamethrin bioassay responses of transgenic flies expressing pyrethroid metabolizing P450s alone or along engineered target-site resistance mutations in their voltage-gated sodium channel (para).
| strain/cross | LD50 (ng fly−1) | (95% FL) | slope (±s.e.) | RR |
|---|---|---|---|---|
| HR-GAL4 × yw; attP40 | 3.10 | (2.65–3.65) | 3.59 (±0.47) | 1 |
| HR-GAL4 × UAS-CYP6BQ23 | 17.8 | (12.50–21.65) | 4.27 (±0.87) | 5.74 |
| yw;HR-GAL4>UAS-CYP9J28(2N)a | 5.49 | (4.051–6.60) | 4.4 (±1.09) | 1.77 |
| nos.Cas9 | 3.33 | (1.3–5.1) | 2.259 (±0.39) | 1.07 |
| paraL1014F | 39.49 | (23.1–53.95) | 2.949 (±0.39) | 12.74 |
| paraV1016G | 9.30 | (4.98–14.55) | 1.696 (±0.36) | 3.00 |
| paraL1014F; HR-GAL4>UAS-CYP6BQ23b | 233.08 | (161.70–333.85) | 1.508 (±0.21) | 75.19 |
| paraV1016G; HR-GAL4>UAS-CYP9J28(2N)c | 61.53 | (47.48–78.50) | 4.851 (±0.80) | 19.85 |
ahomozygous recombinant yw; HR-GAL4>UAS-CYPJ28(2N) contains two copies of driver and responder.
bparaL1014F; HR-GAL4 × paraL1014F; UAS-CYP6BQ23.
cparaV1016G; HR-GAL4>UAS-CYPJ28(2N) contains two copies of driver and responder in paraV1016G X-chromosome background.